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n the years following the publication of major clinical
trials, we commonly see additional articles related to
the original study. These provide data on subgroup
analyses, specific secondary outcomes, extended follow-
up, analyses that were available at the time of publication of
the original article but not included in the manuscript, and
data generated in the years after the original publication
such as genetic and biomarker studies in stored samples.
Although such articles often provide important information,
they are also often underpowered and only of subspecialist
interest. Apart from their scientific value, they offer inves-
tigators who played less prominent roles in the original
article, the opportunity to publish first-author articles and a
wider range of journals the opportunity to get their piece of
the cake where the original study has been published in a
higher ranking journal.
The Systolic Blood Pressure Intervention Trial (SPRINT)
[1] is clearly a landmark trial that has already reshaped
contemporary blood pressure guidelines [2,3]. Not surpris-
ingly we have read over the last couple of years, a large
number of additional analyses deriving from SPRINT, which
addressed important issues including outcomes by race and
ethnicity; outcomes by baseline DBP; visit-to-visit blood
pressure variability; outcomes in people with and without
chronic kidney disease; and comparisons with other land-
mark studies into intensive blood pressure-lowering strate-
gies or treatment of patients at high cardiovascular risk. In
the current issue of Journal of Hypertension, we find a
particularly important analysis of SPRINT in an article by
Foy et al. [4].Journal of Hypertension 2018, 36:768–770
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768 www.jhypertension.comFoy et al. [4] have studied whether the benefits of
intensive SBP lowering extends to both men and women
by separately analysing data from male and female SPRINT
participants. The authors have shown that the primary
composite endpoint was reduced by 16% in women and
by 27% in men with no interaction between treatment and
sex. The lack of statistical interaction indeed suggests that
the overall SPRINT data are not grossly different between
men and women.
One may argue that a sex-specific subgroup analysis in
SPRINT is not necessary. Even if SPRINT did not stratify
treatment by sex, men and women were equally repre-
sented in the two treatment groups, and the analyses were
statistically adjusted for sex. The randomization process
and a sufficiently large sample size should indeed guaran-
tee that there are no significant baseline differences
between treatment arms. Following this line of argument,
however, one would then not only query the importance of
the present sex-specific analysis by Foy et al. [4] but also the
need for adjustment for sex in the first place.
Clearly, adjustment by statistical means cannot take
biological variability fully into account. This is particularly
true with regard to biological and other differences
between men and women that cannot be represented by
a binary ‘sex’ variable in statistical analysis. There are
biological processes that are specific to women at different
stages of their lives that are far more complex than a simple
binary variable and include menarche, the contraceptive
pill, pregnancy and menopause. Of course, there are also
male-specific biological conditions, and features in both
sexes that extend beyond the simplistic binary variable and
include societal expectations, interaction with peers and
other aspects covered by the wider term of gender. There
is a growing body of evidence that all of these, affect
cardiovascular health [5].
In the field of hypertension, numerous differences
between men and women have been recognized. These
range from different prevalence of hypertension (more
prevalent in men until the fifth decade; more prevalent
in women at higher age [6] to higher prevalence of white-
coat hypertension in women [7] whereas these are less
evident when we consider how blood pressure translates
to organ damage such as stroke [8]. Despite the immediately
plausible notion that men and women are different,
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released Report of the American College of Cardiology/
American Heart Association Task Force on Clinical Practice
Guidelines states: ‘Other than special recommendations for
management of hypertension during pregnancy, there is no
evidence that the [blood pressure] threshold for initiating
drug treatment, the treatment target, the choice of initial
antihypertensive medication, or the combination of med-
ications for lowering [blood pressure] differs for women
versus men’ [3].
Where this and other reports refer to ‘no evidence’ it
means to some extent ‘lack of evidence.’ Or to say it more
bluntly, ‘absence of evidence’ does not mean ‘evidence of
absence.’ It is well known that women have traditionally
been underrepresented in cardiovascular trials that form the
basis for evidence-led guidelines. Foy et al. [4] refer to the
article by Westerman and Wenger [9] that nicely summa-
rizes this clinical problem. In fact, this extends to other
conditions such as diabetic nephropathy where women are
also underrepresented. Extreme examples such as the VA-
NEPHRON D study [10] that included only 1% women can
be explained by its recruitment strategy from the Veterans
Affairs system – a source that also fed into SPRINT and
explains in part why there also were fewer women (36%)
than men (64%) in this trial.
The SPRINT study, like many other well designed ran-
domized clinical trials, benefits from a large sample size that
to some extent removes male and female specific factors
across the treatment groups. It is, therefore, not surprising
that the subgroup analysis by Foy et al. [4] does not change
the overall message of SPRINT. Yet again, this subgroup
analysis painfully reminds us of the underrepresentation of
women in a landmark cardiovascular trial. Despite the
absence of a significant interaction between men and
women in the present analysis, it should be noted that
the hazard ratio for the primary endpoint in intensively
treated women (0.84; 95% CI 0.61–1.13) did not reach
statistical significance. Clearly the early termination of
SPRINT for benefit has posed challenges on the statistical
workup of the data and the study has a priori not been
powered for sex-specific analyses. However, the fact that
only approximately a third of the study participants were
women did not help in this context.
The article by Foy et al. [4] comes with bad news for the
busy reader. Those who simply glance over the abstract will
not be surprised by the results. However, to fully appreciate
the value of this article, one has to take some time and dig
deeper into the data. It cannot be a task for this editorial
commentary to guide the reader through the article but we
would still like to highlight one particular aspect within the
data by Foy et al. The reader will notice in Table 1 of the
article that baseline characteristics were overall similar in
the standard versus intensive treatment groups in both men
and women. This is expected if randomization has been
performed well. However, the same table (column I) high-
lights striking differences in baseline characteristics
between all men and women. As it is always the case in
large sample sizes, the P values for significant differences
are very low (<0.001) but more importantly there are quite
substantial numerical differences in factors such as smoking
(7.8 packyears in women versus 14.9 in men) and physicalJournal of Hypertensionactivity (35.3% of women report ‘rarely or never’ versus
22.5% of men). As a community of physicians with an
interest in hypertension and cardiovascular risk, we must
be alarmed by the underuse of ACE inhibitors (31.4 versus
40% in men) and of statins in women (43.9 versus 54.6% in
men). It is this level of detail that is provided in the article by
Foy et al. [4] and that explains why such complex differ-
ences cannot always be reliably addressed by statistical
adjustment for sex. Much more detailed analysis of sex
differences as exemplified in a study by Huxley et al. [11]
where age and regional differences have been taken into
account, which is required to ultimately provide the data
that can then inform clinical guidelines.
As clinicians, we should still be proud that we have at
least recognized the importance of sex and gender in our
studies. A recent analysis of National Heart, Lung, and
Blood Institute (NHLBI) funded research shows an increase
in spending from $0.5 million in 1991 to $18.3 million in
2014 in research into sex differences in hypertension [12]. In
contrast, in basic science research, which provides us with
so important data on underlying mechanisms of clinical
observations, it has been ‘very rare that male and female
animals are studied side by side’ [13]. This notion has only
recently translated into a new American Heart Association
recommendation on design, execution and reporting of
animal atherosclerosis studies, stating that ‘it is advisable
to include sufficient mice of both sexes to permit sex-
specific analysis of atherosclerosis. It is strongly recom-
mended that reported data be segregated by sex’ [14].
At this point we do not want the interested reader to
spend more time on this editorial commentary but would
rather encourage them to study the article by Foy et al. [4] in
this issue of the journal. We hope that the data will be
explored in depth by many in the hypertension community
and that this article will influence future design of clinical
trials and, ultimately, clinical practice.
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